Publication:
Observational study of immunosuppressive treatment patterns and outcomes in primary membranous nephropathy: a multicenter retrospective analysis

dc.contributor.authorArtan A. S.
dc.contributor.authorMİRİOĞLU Ş.
dc.contributor.authorHocaoglu R. H.
dc.contributor.authorTURGUTALP K.
dc.contributor.authorBoz S. E. G.
dc.contributor.authorEREN N.
dc.contributor.authorDincer M. T.
dc.contributor.authorUzun S.
dc.contributor.authorSahin G.
dc.contributor.authorKUTLAY S.
dc.contributor.authoret al.
dc.date.accessioned2024-10-29T21:50:21Z
dc.date.available2024-10-29T21:50:21Z
dc.date.issued2024-10-01
dc.description.abstractBackground We evaluated the efficacy of different immunosuppressive regimens in patients with primary membranous nephropathy in a large national cohort. Methods In this registry study, 558 patients from 47 centers who were treated with at least one immunosuppressive agent and had adequate follow-up data were included. Primary outcome was defined as complete (CR) or partial remission (PR). Secondary composite outcome was at least a 50% reduction in estimated glomerular filtration (eGFR), initiation of kidney replacement therapies, development of stage 5 chronic kidney disease, or death. Results Median age at diagnosis was 48 (IQR: 37-57) years, and 358 (64.2%) were male. Patients were followed for a median of 24 (IQR: 12-60) months. Calcineurin inhibitors (CNIs) with or without glucocorticoids were the most commonly used regimen (43.4%), followed by glucocorticoids and cyclophosphamide (GC-CYC) (39.6%), glucocorticoid monotherapy (25.8%), and rituximab (RTX) (9.1%). Overall remission rate was 66.1% (CR 26.7%, PR 39.4%), and 59 (10.6%) patients reached secondary composite outcome. Multivariate logistic regression showed that baseline eGFR (OR 1.011, 95% CI: 1.003-1.019, p = 0.007), serum albumin (OR 1.682, 95% CI: 1.269-2.231, p < 0.001), and use of RTX (OR 0.296, 95% CI: 0.157-0.557, p < 0.001) were associated with remission rates; whereas only lower baseline hemoglobin was significantly associated with secondary composite outcome (OR: 0.843, 95% CI: 0.715-0.993, p = 0.041). CYC use was significantly associated with higher remission (OR 1.534, 95% CI: 1.027-2.290, p = 0.036). Conclusions Higher baseline eGFR and serum albumin levels correlated with increased remission rates. Remission rates were lower in patients treated with RTX, while those on GC-CYC showed higher rates of remission. Due to the study\"s retrospective nature and multiple treatments used, caution is warranted in interpreting these findings.
dc.identifier.citationArtan A. S., MİRİOĞLU Ş., Hocaoglu R. H., TURGUTALP K., Boz S. E. G., EREN N., Dincer M. T., Uzun S., Sahin G., KUTLAY S., et al., "Observational study of immunosuppressive treatment patterns and outcomes in primary membranous nephropathy: a multicenter retrospective analysis", BMC NEPHROLOGY, cilt.25, sa.1, ss.327-0, 2024
dc.identifier.doi10.1186/s12882-024-03784-8
dc.identifier.issn1471-2369
dc.identifier.issue1
dc.identifier.pubmed39354386
dc.identifier.scopus85205527502
dc.identifier.urihttps://hdl.handle.net/20.500.12645/39748
dc.identifier.volume25
dc.identifier.wosWOS:001326720700004
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectNefroloji
dc.subjectSağlık Bilimleri
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectNephrology
dc.subjectHealth Sciences
dc.subjectÜroloji Ve Nefroloji
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (Med)
dc.subjectUrology & Nephrology
dc.subjectClinical Medicine
dc.subjectClinical Medicine (Med)
dc.subjectÜroloji
dc.subjectUrology
dc.titleObservational study of immunosuppressive treatment patterns and outcomes in primary membranous nephropathy: a multicenter retrospective analysis
dc.typearticle
dspace.entity.typePublication
local.avesis.id356ac6a7-7546-4bac-b515-fce669fa4d06
local.indexed.atPubMed
local.indexed.atWOS
local.indexed.atScopus

Files